The bioestadistic and epidemiologist Martin Kullldorff, MD, PHD and Dr. Mina Zadeh, Executive Secretary of ACIP, CDC, observe that people present their information to the members of the Advisory Committee on Immunization Practices, such as the Disease Control and Prevention Centers (CDC) of the Diseases Center (CDC) of the advisory panel of the vaccines. June 2025.
Megan varner | Reuters
A version of this article appeared for the first time in the Healthy Bulletin returns from CNBC, which brings the latest medical care news directly to its entrance tray. Subscribe here To receive future editions.
A renewed panel of the Government of Vaccine Advisors with newly appointed immunization skeptics has voted against a triggered ingredient containing mercury that the Anti -Baccine movement has attacked for a long time.
The group called the Immunization Practices Advisory Committee, or ACIP, voted on Thursday to recommend annual dose vaccines to the flu to Americans and against influenza shots containing scammerous, despite the fact that there is no evidence of damage due to that preservative. It was the first Acip meeting since the Secretary of Health and Human Services, Robert F. Kennedy Jr., destroyed the panel and stacked it with new members, including several skeptics of known vaccines.
Centers for disease control and prevention must still sign that recommendation. If the agency does, it would affect approximately 4% to 5% of the supply of the US flu vaccine.
According to the CDC data, the rest of the Vaccines against the Flu of the Nation did not have timerosal during the last season of the virus. But when it comes to vaccinating an entire country, “the small percentages are important,” Dr. Sean O'Leary told reporters, an expert in infectious diseases of the American Academy of Pediatrics.
If the few flu vaccines containing thimerosal were removed from the market,
“That would inevitably lead to less vaccinated people, at least in the short term, perhaps in the long term, and subsequently more hospitalizations and deaths,” O'Leary said.
The recommendation also reinforces the unfounded and unfounded fears that the substance can lead to developmental disabilities, such as autism. The skepticism of Kennedy's vaccines is complete with the vote of the panel: a decade before participating in its current role, he published a book that required the elimination of Thimerosal from the shooting and linked it to development disorders.
“A very common antivacuna conversation issue is around Thimerosal, so it is a very clear strategy to sow distrust of vaccines,” O'Leary said.
Susana Sánchez, a practicing nurse, manages a vaccination against flu to Loisy Barrera in a CVS and Minuteteclinic pharmacy on September 10, 2021 in Miami, Florida.
Joe Raedle | Getty images
Here is why the timerosal is important. It has been widely used for decades as a preservative to prevent the growth of harmful bacteria in several medications and vaccines with multiple doses. More than 40 studies for many decades have not found any link between the thimerosal and development delays.
But its use in approved vaccines has been reduced sharply as manufacturers have moved to package a single dose for their shots, which does not require preservatives. The food and medication administration around 25 years ago asked manufacturers to eliminate the substance of children's vaccines as a precaution, not due to evidence of damage, according to CDC.
“The idea was, well, Mercury is a word of terrifying sound, and let's get it, let's make this a problem,” O'Llearly said. He added that “many studies have shown that it is completely safe, it is not associated with any neurod development disorder or any other adverse effect.”
Some multiple dose forms of adult flu vaccines still contain timerosal, including the slope of Sanofi and two shots of the CSL Seqirus biotechnological company.
A panel member, Dr. Cody Meissner, a professor of pediatrics at the Dartmouth Geisel School of Medicine, said he was worried that the use of multid roads could increase could increase the cost of vaccination and limit access to some groups. He also expressed concern about the message that the recommendation would send to other countries where the use of multiprosis flu vaccines is more common.
“That could limit the availability of the influenza vaccine for some people,” he said during the meeting after voting against restricting vaccines against thimerous flu.
Before the votes at the meeting, Lyn Redwood, a practicing nurse who has been involved with antivachamic organizations, presented in Thimerosal in flu vaccines. Redwood is among the “Mercury Moms” that pressed Kennedy to get involved with Mercury and the health of children. It has also served for years as president of Health Defense of Children, the Anti -Caacuna organization founded by Kennedy.
Do not hesitate to send any advice, suggestion, stories ideas and data to Annika in [email protected].
The latest in Medical Care Technology: Arcadia acquired by the private capital firm Nordic Capital
The Arcadia medical care data platform has been acquired by the private capital firm Nordic Capital, companies announced on Tuesday.
Arcadia converts medical care data into predictive ideas that payers and suppliers can use to help improve patients, reduce costs and increase income. The company characterized the agreement with Nordic Capital as a “strategic association” where the company will become the “majority owner” of Arcadia, according to a statement.
Michael Meucci, CEO of Arcadia, said that working with Nordic Capital will allow Arcadia to continue improving his client experience, expanding his artificial intelligence capabilities, exploring new opportunities for mergers and acquisitions and boosting growth in his central segments, including value -based attention.
“It's very validant,” Meucci told CNBC in an interview. “It is validating that there are institutional investors of great capitalization that are so committed to the transformation of medical care (USA) and global medical care as we have been.”
Arcadia and Nordic Capital did not reveal the terms of the acquisition. The agreement is expected to close in the second half of the year, although it is still subject to regulatory approvals.
Meucci said he knows the Nordic capital team for a couple of years, and that the company had been watching Arcadia's progress as a business. Arcadia is profitable and carried out a successful acquisition last year. Meucci said these milestones helped Nordic Capital to feel safe that the company was ready for its next growth stage.
Arcadia last raised external funds in 2023, when she announced $ 125 million in Vista Credit Partners financing. The acquisition of Nordic Capital serves as an exit for previous investors, said Arcadia.
“This association is aligned without problems with the investment strategy of Nordic Capital and Nordic Capital is excited to support Arcadia in its next phase of growth,” Daniel Berglund, partner and co-Cabeza of Medical Care in Nordic Capital said in a statement.
Tripletrese served as Nordic Capital Financial Advisor for the transaction, and Lazard advised Arcadia.
“This is just a new reinforcement of our mission, which we have to change the cost of medical care,” said Meucci.
Read the complete launch here.
Do not hesitate to send any advice, suggestion, stories ideas and data to Ashley at [email protected].
